Best of The In Vivo Blog, April 2010
Executive Summary
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog.
You may also be interested in...
Health Care Reform: For Biopharmas There Is Much To Like
The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks to Generics Bulletin about how the firm is gearing up to launch three key products.
Pivotal Opportunity For UK Medtech Must Not Be Wasted
The UK continues to work on its new medtech regulatory system and market access processes for innovations, but all the planning and preparations will count for little if not accompanied by sound execution, warns Lincoln Tsang of law firm Ropes & Gray.